| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8213486 | International Journal of Radiation Oncology*Biology*Physics | 2016 | 31 Pages |
Abstract
In this large national cohort, dose escalation >50.4Â Gy did not result in improved OS among patients with stage I to III esophageal cancer treated with definitive concurrent radiation and chemotherapy. These data suggest that despite advanced contemporary treatment techniques, OS for patients with esophageal cancer remains unaltered by escalation of radiation dose >50.4Â Gy, consistent with the results of the INT-0123 trial. Furthermore, these data highlight that many radiation oncologists have not embraced the concept that dose escalation does not improve OS. Although local control, not investigated in the present study, might benefit from dose escalation, novel therapies are needed to improve the OS of patients with esophageal cancer.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Jeffrey V. MD, PhD, Shuai PhD, Michael F. MD, PhD, Menggang PhD, Paul M. MD, Mark A. MD, PhD, Andrew M. MD,